The TRIPS Council continued to promote transparency in WTO members’ intellectual property (IP) systems and reviewed implementation of the TRIPS Agreement. It discussed access to medicines, biodiversity, traditional knowledge, the patentability of life forms, biotechnology and technical cooperation, among other topics. The Council extended until January 2033 a waiver on least-developed countries (LDCs) having to apply TRIPS provisions on pharmaceutical patents. It also recommended a parallel waiver of LDC obligations regarding two other TRIPS provisions regarding pharmaceutical products. The Council discussed aspects of innovation policy, including the role of IP in financing innovation.
Ebook ISBN: 9789287040671 Book DOI : https://doi.org/10.30875/7aa07546-en Related Topics: The WTO ; Trade monitoring-contentType:WorkingPaperSeries -contentType:Periodical -contentType:BookSeries -contentType:ReportSeries
/content/books/9789287040671s009-c007 dcterms_subject,pub_countryId-contentType:WorkingPaperSeries -contentType:Periodical -contentType:BookSeries -contentType:ReportSeries
